Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

ABSTRACT:

Importance

THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce.

Objective

To evaluate and compare the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.

Design

Real-world, multicenter retrospective study conducted from 2020 to 2024.

Setting

Five large breast cancer centers in China.

Participants

A total of 145 patients with HER2-positive MBC were included before propensity score matching (PSM). After PSM, 76 patients (38 in each group)

SUBMITTER: Liu B 

PROVIDER: S-EPMC12497480 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature